Johnson & Johnson revised earnings guidance for the full year of 2024. For the year, the company expected operational sales to be in the range of $88.7 billion to $89.1 billion as compared to previous guidance of $88.2 billion to $89.0 billion and estimated reported sales to be in the range of $88.0 billion to $88.4 billion as compared to previous guidance of $87.8 billion to $88.6 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.7 USD | +0.85% | +2.50% | -2.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.60% | 367B | |
+35.01% | 709B | |
+30.81% | 595B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.66% | 239B | |
+9.43% | 211B | |
-3.68% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024